MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview



Anti-Cancer Agents in Medicinal Chemistry, 15(6): 694-700.

Author(s): Carmelo Tibaldi, Armida D’Incecco and Alessandro Lagana.

Affiliation: Division of Oncology- Department of Oncology, Azienda USL-6 of Livorno, Viale Alfieri 36, 57100 LIVORNO, Italy.

Abstract

The discovery of driver oncogene alterations in non-small cell lung cancer (NSCLC), such as EGFR, EML4-ALK, MET and RAS, as well as the identification of their specific targeted inhibitors have led to new opportunities for treatment of this tumor.

Drug resistance, intrinsic or acquired, represents the major cause of failure of novel biological agents.

MicroRNAs (miRNAs) are a family of small non-coding RNAs that can silence their cognate target genes by specifically binding mRNAs or inhibiting their translation. The recent evidences that several micro-RNAs can modulate the oncogenic driver pathways in NSCLC and that they are involved in drug resistance of their targeted inhibitors, have paved the way for new therapeutic strategies.

This minireview aims 1) to explore the potential mechanisms by which key miRNAs may up-regulate or down-regulate specific oncogenic driver pathways; 2) highlight the role of microRNAs in the mechanisms of resistance to targeted therapies; 3) discuss the therapeutic potential by using short-interfering RNAs or artificial miRNAs as anti-cancer therapies.





Keywords:

EGFR, EML4-ALK, Micro-RNA, NSCLC, targeted therapy.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 15
Issue Number: 6
First Page: 694
Last Page: 700
Page Count: 7
DOI: 10.2174/1871520615666150121122054
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science